Prise en charge globale des carcinomes épidermoïdes de la tête et du cou (CETEC) en 2015

Renaud-Salis JL, Blanc-Vincent MP, Brugère J, et al. (1999) Standards, options and recommendations (SOR) for clinical care of squamous cell carcinoma of the oropharynx. Groupe de travail SOR. Bull Cancer 86: 550–72 Pfister DG, Ang K, Brockstein B, et al. (2000) NCCN Practice Guidelines for Head and Neck Cancers. Oncology 14: 163–94 Forastiere A, Koch W, Trotti A et al. (2001) Head and neck cancer. N Eng J Med 345: 1890–900 Grégoire V, Lefebvre JL, Licitra L, et al. (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: v184–v6 Mesía R, Pastor M, Grau JJ, et al. (2013) SEOM clinical guidelines for the treatment of head and neck cancer (HNC). Clin Transl Oncol 15: 1018–24 Pfister DG, Spencer S, Brizel DM, et al. (2014) Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 12: 1454–87 Sinha P, Piccirillo JF, Kallogjeri D, et al. (2015) The role of postoperative chemoradiation for oropharynx carcinoma: a critical appraisal of the published literature and National Comprehensive Cancer Network guidelines. Cancer [Epub ahead of print] Bardet E, Bourhis J, Cals L, et al. (2009) Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy. Bull Cancer 96: 1013–28 Forastiere AA (2010) Larynx preservation and survival trends: should there be concern? Head Neck 32: 14–7 J. Guigay (2011) State of the art in the treatment of larynx tumours. Radiother Oncol 98: S15 Levy A, Blanchard P, Bellefqih S, et al. (2014) Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas. Anticancer Drugs 25: 1220–6 Vermorken JB, Mesia R, Rivera F, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116–27 Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21: 252–61 Peyrade F, Cupissol D, Geoffrois L, et al. (2013) Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. Oral Oncol 49: 482–91 Pignon JP, Maillard E, et al. (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92: 4–14 Lörincz BB, Jowett N, Knecht R (2015) Decision management in transoral robotic surgery (TORS): Indications, individual patient selection, and role in the multidisciplinary treatment of head and neck cancer from a European perspective. Head Neck [Epub ahead of print] Nutting CM, Morden JP, Harrington KJ, et al. (2011) Parotidsparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase III multicentre randomised controlled trial. Lancet Oncol 12: 127–36 Valentini V, Van Stiphout RGPM, Lammering G, et al. (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29: 3163–72 Valentini V, Dinapoli N, Damiani A (2013) The future of predictive models in radiation oncology: from extensive data mining to reliable modeling of the results. Future Oncol 9: 311–3 Guigay J, Le Caer H, Mertens C, et al. (2014) ELAN (ELderly Head and Neck Cancer) study: Personalized treatment according to geriatric assessment in patients aged 70 or over: First prospective trials in patients with squamous cell cancer of the head and neck (SCCHN), unsuitable for surgery. J Clin Oncol 32: 5s (suppl; abstr TPS6099) Mirghani H, Amen F, Blanchard P, et al. (2015) Treatment deescalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer 136: 1494–503 Brizel DM (2015) Different strokes for different folks: new paradigms for staging oropharynx cancer. J Clin Oncol 33: 817–8 Guigay J, Fayette J, Dillies AF, et al. (2012) Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03. J Clin Oncol [suppl; abstr 5505] Guigay J, Keilholz U, Mesia R, et al. (2015) TPExtreme randomized trial: docetaxel–platinum(P)–cetuximab(C) versus 5-FU-P-C in recurrent/metastatic HNSCC. Radiother Oncol 114 (Suppl 1, abstr PO-091) Machiels JP, Haddad RI, Fayette J, et al. (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase III trial. Lancet Oncol [Epub ahead of print] Guigay J, Peyrade F, Saada E (2015) The role of PD-L1/PD1 pathway in SCCHN. Radiother Oncol 114: 12, abstr SP-052 The Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517: 576–82 Even C, Breuskin I, Ileana E, et al. (2015) Molecular screening for cancer treatment optimization in head and neck cancer (MOSCATO 01). Radiother Oncol 114 (suppl 1): 12 (abstr OC-014)